INSIGHTS ON ENTERPRISE SOLUTIONS

• Why Commercial Ready Manufacturing Should Be Considered From Day One

  Early process decisions can determine whether cell therapies scale efficiently. Explore how automation, robotics, facility design, and manufacturing expertise can reduce batch costs.

• Behind The Data: Leveraging Protein And gRNA Engineering

  See how coordinated optimization of the nickase, deaminase, and guide RNA can increase base editing potency, reduce bystander edits, and improve specificity when an initial candidate falls short.

• Behind The Data: Active Learning-Guided Optimization

  Active learning can accelerate protein engineering by identifying high-performing mutations, revealing interactions between variants, and guiding higher-order designs that improve targeted gene insertion.

• Behind The Data: Leveraging Generative AI

  Combining generative protein design, computational filtering, and experimental feedback produced a de novo deaminase with greater than 20% on-target editing and less than 1% bystander activity.

• Behind The Data: Next‑Generation Enzymes For Targeted Gene Insertion

  9/23/2026

  Large serine recombinases enable efficient insertion of sizable genetic cargo without exposed double-strand breaks, creating new opportunities for precise engineering in therapeutically relevant cells.

• Behind The Data: Engineering Hepatocyte-Targeted LNPs

  9/23/2026

  See how lipid nanoparticle platforms can deliver RNA and large DNA payloads to primary human T cells, improving transfection, expression durability, and CAR insertion efficiency.

• Behind The Data: Comprehensive Off-Target Assessment Strategies

  9/23/2026

  Explore how biochemical, computational, and cell-based methods can identify, confirm, and interpret off-target editing risks, providing a more complete safety assessment for CRISPR-based therapeutics.

• Behind The Data: Iterative Engineering And Optimization Strategies

  9/23/2026

  See how iterative optimization across RNA chemistry, lipid nanoparticle formulation, protein engineering, and preclinical testing can improve in vivo liver editing potency and accelerate progression.